Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 177

1.

Long-term biochemical progression-free survival following brachytherapy for prostate cancer: Further insight into the role of short-term androgen deprivation and intermediate risk group subclassification.

Matzkin H, Chen J, Agai R, Ziv-Baran T, Mabjeesh NJ.

PLoS One. 2019 Apr 19;14(4):e0215582. doi: 10.1371/journal.pone.0215582. eCollection 2019.

2.

Can urologists accurately stage and grade urothelial bladder cancer by assessing endoscopic photographs?

Dekalo S, Matzkin H, Mabjeesh NJ.

J Telemed Telecare. 2018 Oct;24(9):603-607. doi: 10.1177/1357633X17727773. Epub 2017 Sep 18.

PMID:
28920525
3.

High cancer detection rate using cognitive fusion - targeted transperineal prostate biopsies.

Dekalo S, Matzkin H, Mabjeesh NJ.

Int Braz J Urol. 2017 Jul-Aug;43(4):600-606. doi: 10.1590/S1677-5538.IBJU.2016.0511.

4.

A Novel Urine-Based Assay for Bladder Cancer Diagnosis: Multi-Institutional Validation Study.

Davis N, Shtabsky A, Lew S, Rona R, Leibovitch I, Nativ O, Cohen M, Mor Y, Lindner U, Glickman Y, Matzkin H, Tsivian A, Gofrit O, Yossepovitch O.

Eur Urol Focus. 2018 Apr;4(3):388-394. doi: 10.1016/j.euf.2016.10.004. Epub 2016 Oct 31.

PMID:
28753799
5.

Implementation of supine percutaneous nephrolithotomy: a novel position for an old operation.

Sofer M, Tavdi E, Levi O, Mintz I, Bar-Yosef Y, Sidi A, Matzkin H, Tsivian A.

Cent European J Urol. 2017;70(1):60-65. doi: 10.5173/ceju.2017.1222. Epub 2017 Mar 14.

6.

Upper Calyx Accessibility Through a Lower Calyx Access Is Not Influenced by Morphometric and Clinical Factors in Supine Percutaneous Nephrolithotomy.

Sofer M, Barghouthy Y, Bar-Yosef Y, Mintz I, Proietti S, Tsemah R, Horkin A, Matzkin H, Giusti G.

J Endourol. 2017 May;31(5):452-456. doi: 10.1089/end.2016.0823. Epub 2017 Apr 14.

PMID:
28292191
7.

Sulfadiazine-Induced Obstructive Nephropathy Presenting with Upper Urinary Tract Extravasation.

Kabha M, Dekalo S, Barnes S, Mintz I, Matzkin H, Sofer M.

J Endourol Case Rep. 2016 Sep 1;2(1):159-161. eCollection 2016.

8.

Upper Calyx Approachability through a Lower Calyx Access for Prone Versus Supine Percutaneous Nephrolithotomy.

Sofer M, Giusti G, Proietti S, Mintz I, Kabha M, Matzkin H, Aviram G.

J Urol. 2016 Feb;195(2):377-82. doi: 10.1016/j.juro.2015.07.101. Epub 2015 Aug 6.

PMID:
26254723
9.

[Position statement for the diagnosis and treatment of men with benign prostate enlargement and lower urinary tract symptoms].

Greenstein A, Ferman Z, Stav K, Gruenwald I, Matzkin H, Ramon J.

Harefuah. 2014 Sep;153(9):546-9, 557. Hebrew.

PMID:
25417493
10.
11.

HIF1A C1772T polymorphism leads to HIF-1α mRNA overexpression in prostate cancer patients.

Vainrib M, Golan M, Amir S, Dang DT, Dang LH, Bar-Shira A, Orr-Urtreger A, Matzkin H, Mabjeesh NJ.

Cancer Biol Ther. 2012 Jul;13(9):720-6. Epub 2012 May 31.

PMID:
22647679
12.

High detection rate of significant prostate tumours in anterior zones using transperineal ultrasound-guided template saturation biopsy.

Mabjeesh NJ, Lidawi G, Chen J, German L, Matzkin H.

BJU Int. 2012 Oct;110(7):993-7. doi: 10.1111/j.1464-410X.2012.10972.x. Epub 2012 Mar 6.

13.

Non-contrast computed tomography after percutaneous nephrolithotomy: findings and clinical significance.

Sofer M, Druckman I, Blachar A, Ben-Chaim J, Matzkin H, Aviram G.

Urology. 2012 May;79(5):1004-10. doi: 10.1016/j.urology.2011.11.022. Epub 2012 Feb 4.

PMID:
22305762
14.

Validation and comparison of the two Kattan nomograms in patients with prostate cancer treated with (125) iodine brachytherapy.

Kaplan A, German L, Chen J, Matzkin H, Mabjeesh NJ.

BJU Int. 2012 Jun;109(11):1661-5. doi: 10.1111/j.1464-410X.2011.10748.x. Epub 2011 Nov 24.

15.

Endourological procedures and sexual dysfunction: a prospective multivariate analysis.

Sofer M, Yehiely R, Greenstein A, Bar-Yosef Y, Matzkin H, Chen J.

BJU Int. 2012 Jan;109(2):250-3. doi: 10.1111/j.1464-410X.2011.10232.x. Epub 2011 Apr 20.

16.

Tubeless percutaneous nephrolithotomy: first 200 cases in Israel.

Sofer M, Lidawi G, Keren-Paz G, Yehiely R, Beri A, Matzkin H.

Isr Med Assoc J. 2010 Mar;12(3):164-7.

17.

Long-term results of early endoscopic realignment of complete posterior urethral disruption.

Sofer M, Mabjeesh NJ, Ben-Chaim J, Aviram G, Bar-Yosef Y, Matzkin H, Kaver I.

J Endourol. 2010 Jul;24(7):1117-21. doi: 10.1089/end.2010.0069.

PMID:
20590470
18.

The role of brachytherapy in the 21st century for prostate cancer.

Mabjeesh NJ, Matzkin H.

Minerva Urol Nefrol. 2010 Jun;62(2):203-11. Review.

PMID:
20562800
19.

Dutasteride and prostate cancer risk.

Matzkin H.

Curr Urol Rep. 2010 Sep;11(5):296-8. doi: 10.1007/s11934-010-0129-1. No abstract available.

PMID:
20556555
20.

Prospective comparison of PSA kinetics following two different prostate cancer brachytherapy planning methods: preoperative and real-time intraoperative dosimetry planning.

Matzkin H, Chen J, Stenger A, Agai R, Mabjeesh NJ.

Urol Oncol. 2012 Jul-Aug;30(4):379-85. doi: 10.1016/j.urolonc.2009.12.001. Epub 2010 Mar 2.

PMID:
20189847
21.

Detection of prostate specific transcripts in the peripheral blood during brachytherapy predicts postoperative PSA kinetics.

Mabjeesh NJ, Amir S, Stenger A, Chen J, Matzkin H.

Prostate. 2009 Aug 1;69(11):1235-44. doi: 10.1002/pros.20977.

PMID:
19434652
22.

Ventral plication for repair of pediatric dorsal penile curvature.

Bar-Yosef Y, Binyamini J, Sofer M, Matzkin H, Ben-Chaim J.

Urology. 2009 Apr;73(4):787-90. doi: 10.1016/j.urology.2008.09.075. Epub 2009 Jan 23.

PMID:
19167038
23.

[Alpha blockers in use for symptomatic benign prostatic hyperplasia--are all drugs born equal?].

Bar-Yosef Y, Mabjeesh NJ, Laufer M, Neulander EZ, Kaver I, Matzkin H.

Harefuah. 2008 Jun;147(6):514-9, 574. Review. Hebrew.

PMID:
18693628
24.

Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice.

Vallancien G, Emberton M, Alcaraz A, Matzkin H, van Moorselaar RJ, Hartung R, Harving N, Elhilali M; ALF-ONE Study Group.

BJU Int. 2008 Apr;101(7):847-52. doi: 10.1111/j.1464-410X.2008.07458.x.

25.

Potentiation of 2-methoxyestradiol-induced cytotoxicity by blocking endothelin A receptor in prostate cancer cells.

Mabjeesh NJ, Shefler A, Amir S, Matzkin H.

Prostate. 2008 May 1;68(6):679-89. doi: 10.1002/pros.20734.

PMID:
18288682
26.

Preimplant predictive factors of urinary retention after iodine 125 prostate brachytherapy.

Mabjeesh NJ, Chen J, Stenger A, Matzkin H.

Urology. 2007 Sep;70(3):548-53.

PMID:
17905113
27.

Extending the application of tubeless percutaneous nephrolithotomy.

Sofer M, Beri A, Friedman A, Aviram G, Mabjeesh NJ, Chen J, Ben-Chaim J, Greenstein A, Matzkin H.

Urology. 2007 Sep;70(3):412-6; discussion 416-7.

PMID:
17905084
28.

[Epidemiological characteristics and trends of testicular cancer in Israel 1992-2002].

Beri A, Matzkin H, Liphshitz I, Barchana M.

Harefuah. 2007 Jul;146(7):515-9, 575. Hebrew.

PMID:
17803163
29.

The role of phosphodiesterase type 5 inhibitors in the management of premature ejaculation: a critical analysis of basic science and clinical data.

Chen J, Keren-Paz G, Bar-Yosef Y, Matzkin H.

Eur Urol. 2007 Nov;52(5):1331-9. Epub 2007 Aug 17. Review.

PMID:
17728050
30.

[Pediatric endourology].

Sofer M, Keren-Paz G, Beniamyni J, Bar-Yosef Y, Matzkin H, Ben-Chaim J.

Harefuah. 2007 Mar;146(3):187-90, 246-7. Hebrew.

PMID:
17460923
31.

Holmium laser ureteroscopic treatment of various pathologic features in pediatrics.

Sofer M, Binyamini J, Ekstein PM, Bar-Yosef Y, Chen J, Matzkin H, Ben-Chaim J.

Urology. 2007 Mar;69(3):566-9.

PMID:
17382169
32.

Degloving and realignment--simple repair of isolated penile torsion.

Bar-Yosef Y, Binyamini J, Matzkin H, Ben-Chaim J.

Urology. 2007 Feb;69(2):369-71.

PMID:
17320680
33.

Survivin expression in the ureteral wall of high degree vesicoureteral reflux in children.

Joseph B, Letizia S, Grisaru D, Bar-Yosef Y, Matzkin H, Ben-Chaim J.

Int Urol Nephrol. 2007;39(1):79-83. Epub 2007 Jan 4.

PMID:
17203351
34.

Dorsal vein injuries observed during penile exploration for suspected penile fracture.

Bar-Yosef Y, Greenstein A, Beri A, Lidawi G, Matzkin H, Chen J.

J Sex Med. 2007 Jul;4(4 Pt 2):1142-6. Epub 2006 Nov 1.

PMID:
17081217
35.
36.

Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms.

Emberton M, Lukacs B, Matzkin H, Alcaraz A, Elhilali M, Vallancien G.

J Urol. 2006 Sep;176(3):1051-6.

PMID:
16890690
37.

Are consecutive nightly recordings required for valid evaluation of sleep-associated erections?

Greenstein A, Mabjeesh NJ, Sofer M, Kaver I, Matzkin H, Chen J.

Int J Impot Res. 2007 Mar-Apr;19(2):196-9. Epub 2006 Aug 3.

PMID:
16885991
38.

Hyperoxaluria in women with vulvar vestibulitis syndrome.

Greenstein A, Militscher I, Chen J, Matzkin H, Lessing JB, Abramov L.

J Reprod Med. 2006 Jun;51(6):500-2.

PMID:
16846091
39.
40.

Mutation screening and association study of the candidate prostate cancer susceptibility genes MSR1, PTEN, and KLF6.

Bar-Shira A, Matarasso N, Rosner S, Bercovich D, Matzkin H, Orr-Urtreger A.

Prostate. 2006 Jul 1;66(10):1052-60.

PMID:
16598737
41.

RNASEL mutation screening and association study in Ashkenazi and non-Ashkenazi prostate cancer patients.

Orr-Urtreger A, Bar-Shira A, Bercovich D, Matarasso N, Rozovsky U, Rosner S, Soloviov S, Rennert G, Kadouri L, Hubert A, Rennert H, Matzkin H.

Cancer Epidemiol Biomarkers Prev. 2006 Mar;15(3):474-9.

42.

Long-term efficacy and safety of alfuzosin 10 mg once daily: a 2-year experience in 'real-life' practice.

Elhilali M, Emberton M, Matzkin H, van Moorselaar RJ, Hartung R, Harving N, Alcaraz A, Vallancien G; ALF-ONE Study Group.

BJU Int. 2006 Mar;97(3):513-9.

43.

[Brachytherapy combined with external beam radiation in localized prostate cancer].

Matzkin H, Mabjeesh N, Stenger A, Agai R, Chen J, Inbar M.

Harefuah. 2006 Jan;145(1):8-12, 80. Hebrew.

PMID:
16450716
44.
45.

Does sildenafil enhance quality of nocturnal erections in healthy young men? A NPT-RigiScan study.

Greenstein A, Chen J, Salonia A, Sofer M, Matzkin H, Montorsi F.

J Sex Med. 2004 Nov;1(3):314-7.

PMID:
16422962
46.

Age, comorbidity and hypertensive co-medication do not affect cardiovascular tolerability of 10 mg alfuzosin once daily.

Hartung R, Matzkin H, Alcaraz A, Emberton M, Harving N, van Moorselaar J, Elhilali M, Vallancien G; ALF-ONE Study Group.

J Urol. 2006 Feb;175(2):624-8; discussion 628.

PMID:
16407011
47.

An evaluation of general and spinal anesthesia techniques for prostate brachytherapy in a day surgery setting.

Flaishon R, Ekstein P, Matzkin H, Weinbroum AA.

Anesth Analg. 2005 Dec;101(6):1656-8.

PMID:
16301237
48.

Does information provided to men before a urodynamic study affect their expectation of pain?

Greenstein A, Bar-Yosef Y, Chen J, Matzkin H.

BJU Int. 2005 Dec;96(9):1307-9.

49.

Megameatus intact prepuce hypospadias variant: application of tubularized incised plate urethroplasty.

Bar-Yosef Y, Binyamini J, Mullerad M, Matzkin H, Ben-Chaim J.

Urology. 2005 Oct;66(4):861-4; discussion 864.

PMID:
16230154
50.

[Endoscopic injection of dextranomer/hyaluronic acid for vesico-ureteral reflux--preliminary results].

Bar-Yosef Y, Binyamini J, Sofer M, Matzkin H, Ben-Chaim J.

Harefuah. 2005 Sep;144(9):613-5, 679, 678. Hebrew.

PMID:
16218529

Supplemental Content

Loading ...
Support Center